409 related articles for article (PubMed ID: 20033410)
21. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
22. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
[TBL] [Abstract][Full Text] [Related]
23. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
Xu W; Tang Y; Song H; Shi S; Yang S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
[TBL] [Abstract][Full Text] [Related]
24. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
25. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
26. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard L; Lilleyman JS
J Clin Oncol; 1989 Dec; 7(12):1816-23. PubMed ID: 2585022
[TBL] [Abstract][Full Text] [Related]
27. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
Berkovitch M; Matsui D; Zipursky A; Blanchette VS; Verjee Z; Giesbrecht E; Saunders EF; Evans WE; Koren G
Med Pediatr Oncol; 1996 Feb; 26(2):85-9. PubMed ID: 8531858
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
[TBL] [Abstract][Full Text] [Related]
30. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
[TBL] [Abstract][Full Text] [Related]
31. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia.
Palle J; Frost BM; Petersson C; Hasle H; Hellebostad M; Kanerva J; Schmiegelow K; Lönnerholm G;
Anticancer Drugs; 2009 Jan; 20(1):7-14. PubMed ID: 19342996
[TBL] [Abstract][Full Text] [Related]
32. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
[TBL] [Abstract][Full Text] [Related]
33. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
34. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
Brackett J; Schafer ES; Leung DH; Bernhardt MB
Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
[TBL] [Abstract][Full Text] [Related]
35. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
36. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
Tatsumoto C; Kawakami K; Nagayama J; Kawano H
Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
38. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Whitehead VM; Shuster JJ; Vuchich MJ; Mahoney DH; Lauer SJ; Payment C; Koch PA; Cooley LD; Look AT; Pullen DJ; Camitta B
Leukemia; 2005 Apr; 19(4):533-6. PubMed ID: 15716987
[TBL] [Abstract][Full Text] [Related]
39. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
40. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]